{"transactions":[{"id":4089568,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2018-01-25T22:02:41.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":54322,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":175658,"derivative":{"exercise_price":0.3,"exercise_date":"2019-01-23","expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":54322},"source":{"system":"sec-edgar","filing":"0000899243-18-001906","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000089924318001906/doc4.xml","form_type":"4"}},{"id":4107019,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-01-05T01:16:36.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0000899243-18-000531","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000089924318000531/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107018,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-05T01:16:36.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017."}],"balance_after":23165,"source":{"system":"sec-edgar","filing":"0000899243-18-000531","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000089924318000531/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107013,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-01-04T22:16:38.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0000899243-18-000484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000089924318000484/doc4.xml","form_type":"4"}},{"id":4107012,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-04T22:16:38.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017."}],"balance_after":16667,"source":{"system":"sec-edgar","filing":"0000899243-18-000484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000089924318000484/doc4.xml","form_type":"4"}},{"id":4154168,"issuer":{"id":170270,"kind":"organization","name":"MetaStat, Inc.","symbol":"MTST"},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2017-11-21T19:53:07.000Z","date":"2017-10-11","kind":"exercise","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-17-001842","document":"form4-11212017_041156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404943/000141588917001842/form4-11212017_041156.xml","form_type":"4"}},{"id":4190849,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2017-10-05T20:18:28.000Z","date":"2017-10-04","kind":"grant","acquired":true,"shares":38106,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":121336,"derivative":{"exercise_price":0.72,"exercise_date":"2018-10-04","expiration_date":"2027-10-04","underlying":"Common Stock","underlying_shares":38106},"source":{"system":"sec-edgar","filing":"0001104659-17-061151","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000110465917061151/a4.xml","form_type":"4"}},{"id":4215750,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-09-07T00:48:14.000Z","date":"2017-09-02","kind":"exercise","acquired":false,"shares":6498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 2, 2017, the reporting person was granted 6,498 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 2, 2017, the reporting person was granted 6,498 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":6498},"source":{"system":"sec-edgar","filing":"0001104659-17-055893","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000110465917055893/a4.xml","form_type":"4"}},{"id":4215749,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-07T00:48:14.000Z","date":"2017-09-02","kind":"exercise","acquired":true,"shares":6498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\"). On January 2, 2017, the reporting person was granted 6,498 restricted stock units, all of which vested on September 2, 2017. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017."}],"balance_after":6498,"source":{"system":"sec-edgar","filing":"0001104659-17-055893","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000110465917055893/a4.xml","form_type":"4"}},{"id":4497977,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-01-05T21:59:11.000Z","date":"2017-01-02","kind":"grant","acquired":true,"shares":6498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs shall vest on September 2, 2017"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs shall vest on September 2, 2017"}],"balance_after":23165,"derivative":{"underlying":"Common Stock","underlying_shares":6498},"source":{"system":"sec-edgar","filing":"0001104659-17-000964","document":"a4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000110465917000964/a4a.xml","form_type":"4/A","original_submission_date":"2017-01-04"}},{"id":4497976,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-01-05T21:59:11.000Z","date":"2017-01-02","kind":"grant","acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest on January 2, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest on January 2, 2018."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001104659-17-000964","document":"a4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000110465917000964/a4a.xml","form_type":"4/A","original_submission_date":"2017-01-04"}},{"id":4501969,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":170080,"kind":"person","name":"Billings Paul","position":1,"cik":"0001591558","reported_name":"Billings Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-01-04T22:01:12.000Z","date":"2017-01-02","kind":"grant","acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest on January 2, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest on January 2, 2018."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001104659-17-000631","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000110465917000631/a4.xml","form_type":"4"}}]}